ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0329

Scoring Personalized Molecular Portraits Identify Systemic Lupus Erythematosus Subtypes and Predict Individualized Drug Responses, Symptomatology and Disease Progression

Daniel Toro-Domínguez1, Manuel Martinez-Bueno1, Raúl López-Domínguez2, Jordi Martorell-Marugán1, Elena Carnero-Montoro1, Guillermo Barturen1, Daniel W. Goldman3, Michelle Petri3, Pedro Carmona-Sáez2 and Marta Alarcon-Riquelme1, 1Center for Genomics and Oncological Research (GENYO), Granada, Spain, 2University of Granada, Granada, Spain, 3Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD

Meeting: ACR Convergence 2022

Keywords: Bioinformatics, Gene Expression, prognostic factors, Systemic lupus erythematosus (SLE), Systems-based Studies

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Systemic Lupus Erythematosus is a complex autoimmune disease that leads to important worsening of quality of life and mortality. Flares appear unpredictably during the disease course and therapies used are often only partially effective. These challenges are mainly due to the molecular heterogeneity of the disease, such that personalized medicine offers major promise. With this work we intended to advance in that direction by developing MyPROSLE, an omic-based workflow for measuring the molecular portrait of individual patients to support clinicians in their therapeutic decisions.

Methods: Immunological gene-modules were used to represent the transcriptome of the patients. A dysregulation score for each gene-module was calculated at the patient level based on averaged z-scores (M-scores). Almost 6100 lupus and 750 healthy samples were used to analyze the association between dysregulation scores, clinical manifestations, prognosis, flare and remission events and drug response to Tabalumab. Machine learning-based classification models were built to predict around 100 different clinical parameters based on personalized dysregulation scores. The system was called MyPROSLE.

Results: MyPROSLE allows to molecularly summarize patients in 206 gene-modules, clustered into 9 main lupus signatures, the combination of which revealed highly differentiated pathological mechanisms. We show that dysregulation of certain gene-modules is strongly associated with specific clinical manifestations, the occurrence of relapses or the potential presence of long-term remission and drug response. Therefore, MyPROSLE could be used to accurately predict these clinical outcomes, example, we can predict severe nephritis (AUC = 0.98) without the need for biopsy.

Conclusion: MyPROSLE (available at https://myprosle.genyo.es) allows molecular characterization of individual Lupus patients and it extracts key molecular information to support more precise therapeutic decisions. Figure 1 shows a summary of the main steps performed on the web tool.

Supporting image 1

Figure 1. Web tool output example. The figure shows a summary of the web output for each of the two main steps, the personalized molecular profiling of the patients by calculating the M-scores and the clinical outcomes prediction.


Disclosures: D. Toro-Domínguez, None; M. Martinez-Bueno, None; R. López-Domínguez, None; J. Martorell-Marugán, None; E. Carnero-Montoro, None; G. Barturen, None; D. Goldman, None; M. Petri, Exagen, AstraZeneca, Alexion, Amgen, AnaptysBio, Argenx, Aurinia, Biogen, Caribou Biosciences, CVS Health, EMD Serono, Eli Lilly, Emergent Biosolutions, GlaxoSmithKline (GSK), IQVIA, Janssen, Kira Pharmaceuticals, MedShr, Sanofi, SinoMab, Thermofisher, BPR Scientific Advisory Committee; P. Carmona-Sáez, None; M. Alarcon-Riquelme, None.

To cite this abstract in AMA style:

Toro-Domínguez D, Martinez-Bueno M, López-Domínguez R, Martorell-Marugán J, Carnero-Montoro E, Barturen G, Goldman D, Petri M, Carmona-Sáez P, Alarcon-Riquelme M. Scoring Personalized Molecular Portraits Identify Systemic Lupus Erythematosus Subtypes and Predict Individualized Drug Responses, Symptomatology and Disease Progression [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/scoring-personalized-molecular-portraits-identify-systemic-lupus-erythematosus-subtypes-and-predict-individualized-drug-responses-symptomatology-and-disease-progression/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/scoring-personalized-molecular-portraits-identify-systemic-lupus-erythematosus-subtypes-and-predict-individualized-drug-responses-symptomatology-and-disease-progression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology